SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
CAMBRIDGE, Mass., Nov. 13, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
- Stifel 2017 Healthcare Conference, New York City
Date: Wednesday, November 15, 2017
Time: 2:00 p.m. EST
Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer
- Piper Jaffray Healthcare Conference, New York City
Date: Tuesday, November 28, 2017
Time: 9:00 a.m. EST
Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer - Evercore ISI Biopharma Catalyst/Deep Dive Conference, Boston, MA
Date: Wednesday, November 29, 2017
Time: 3:30 p.m. EST
Panel Members: Steven Paul, M.D., president and chief executive officer and Jane Henderson, chief financial officer and senior vice president of corporate development
Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
Investor Relations:
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
[email protected]
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
[email protected]
